<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413008</url>
  </required_header>
  <id_info>
    <org_study_id>ITFE-2026-C10</org_study_id>
    <secondary_id>2014-004517-84</secondary_id>
    <nct_id>NCT02413008</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting</brief_title>
  <acronym>BLISSAFE</acronym>
  <official_title>A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multi-Centre Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ITF Research Pharma, S.L.U.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ITF Research Pharma, S.L.U.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, prospective, randomized, double-blind, placebo-controlled, international
      (Spain and Sweden) and multicentre study to explore the safety of 0.005% estriol vaginal gel
      in women with early stage breast cancer in treatment with Non-Steroidal Aromatase Inhibitors
      (NSAIs) in the adjuvant setting and symptoms of vaginal atrophy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, prospective, randomized, double-blind, placebo-controlled, international
      (Spain and Sweden) and multicentre study.

      In the setting of postmenopausal hormone receptor positive breast cancer, treatment with
      aromatase inhibitors (AIs) is the most effective and well-studied therapy. Vaginal dryness is
      one of the most frequently reported symptom caused by this adjuvant therapy which may lead to
      a reduced adherence in breast cancer women.

      This study will explore the safety of 0.005% estriol vaginal gel in this oncological context,
      to demonstrate that this medicinal product is a safe option to treat the vaginal atrophy
      caused by AIs, without a clinically relevant influence in gonadotropins or systemic estrogen
      levels.

      The main objective is to evaluate the levels of Follicle Stimulating Hormone (FSH) after
      treatment with 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women
      with early stage breast cancer in treatment with Non-Steroidal Aromatase Inhibitors (NSAIs)
      in the adjuvant setting and symptoms of vaginal atrophy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2015</start_date>
  <completion_date type="Actual">February 10, 2017</completion_date>
  <primary_completion_date type="Actual">February 10, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation in Serum Levels of Follicle Stimulating Hormone (FSH)</measure>
    <time_frame>from baseline to 12 weeks of treatment</time_frame>
    <description>Change from Baseline (mean screening-baseline) to Week 12 in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability (screening-baseline variation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation in Serum Levels of FSH at Week 1, Week 3 and Week 8</measure>
    <time_frame>Change from baseline to week 1, week 3 and week 8</time_frame>
    <description>Change from Baseline (mean screening-baseline) to Week 1, Week 3 and Week 8 in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability ( screening-baseline variation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in Serum Levels of Luteinizing Hormone (LH)</measure>
    <time_frame>Change from baseline to week 1, week 3, week 8 and week 12</time_frame>
    <description>Change from (mean screening-baseline) in plasma levels of LH to Week 1, Week 3, Week 8 and Week 12 in Serum Levels of LH compare to natural physiological variability ( screening-baseline variation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in Plasma Levels of Estriol</measure>
    <time_frame>Change from baseline to week 1, week 3, week 8 and week 12</time_frame>
    <description>Change in plasma levels of estriol at weeks 1, 3, 8 and 12 compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in Plasma Levels of Estradiol</measure>
    <time_frame>Change from baseline to week 1, week 3, week 8 and week 12</time_frame>
    <description>Change in plasma levels of estradiol at weeks 1, 3, 8 and 12 compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in Plasma Levels of Estrona</measure>
    <time_frame>Change from baseline to week 1, week 3, week 8 and week 12</time_frame>
    <description>Change in plasma levels of estrona at weeks 1, 3, 8 and 12 compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Vaginal pH Between Baseline and Week 3 and Week 12</measure>
    <time_frame>week 3 and week 12 vs baseline</time_frame>
    <description>Measurement of vaginal pH on the vaginal secretion using a reactive strip and compare pH value between baseline and the diferent timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Dyspareunia</measure>
    <time_frame>week 3 and week 12 vs baseline</time_frame>
    <description>Changes in dyspareunia from baseline to week 3 and week 12 Each symptom will be scored in a numeric scale from 0 to 3, as shown 0 Absence. The symptom is not present
The symptom is of mild intensity, without interfering in the patient's activity
The symptom is of moderate intensity, causing obvious discomfort to the patient
The symptom is stated as very irritating and severe in intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pruritus or Itching From Baseline to Week 3 and Week 12</measure>
    <time_frame>Change from baseline to week 3 and week 12</time_frame>
    <description>Change in pruritus or itching from baseline to week 3 and week 12
Each symptom will be scored in a numeric scale from 0 to 3, as shown below:
0 Absence. The symptom is not present
The symptom is of mild intensity, without interfering in the patient's activity
The symptom is of moderate intensity, causing obvious discomfort to the patient
The symptom is stated as very irritating and severe in intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Vaginal Dryness</measure>
    <time_frame>week 3 and week 12 vs baseline</time_frame>
    <description>Change in vaginal dryness puntuation score from baseline to w3 and w12
Each symptom will be scored in a numeric scale from 0 to 3, as shown below:
0 Absence. The symptom is not present
The symptom is of mild intensity, without interfering in the patient's activity
The symptom is of moderate intensity, causing obvious discomfort to the patient
The symptom is stated as very irritating and severe in intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Total Score of Symptoms of Vaginal Atrophy</measure>
    <time_frame>week 3 and week 12 vs baseline</time_frame>
    <description>Changes in Symptoms of vaginal atrophy (vaginal dryness, dyspareunia and pruritus) at week 3 and week 12 vs baseline.
Each symptom will be scored in a numeric scale from 0 to 3, as shown below:
0 Absence. The symptom is not present
The symptom is of mild intensity, without interfering in the patient's activity
The symptom is of moderate intensity, causing obvious discomfort to the patient
The symptom is stated as very irritating and severe in intensity A Global Symptoms Score will be calculated by summing the intensities of all the three symptoms of vaginal atrophy in a certain time point, thus ranging between 0 and 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Dryness of the Mucosa</measure>
    <time_frame>week 3 and week 12 vs baseline</time_frame>
    <description>It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:
0 Absence. The sign is not present.
The sign is present and is considered a mild alteration
The sign is present and is considered a moderate alteration
The sign is present and is considered a severe alteration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Fragility of the Mucosa [Time Frame: Week 3 and Week 12 vs Baseline]</measure>
    <time_frame>from baseline to week 3 and 12</time_frame>
    <description>It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:
0 Absence. The sign is not present.
The sign is present and is considered a mild alteration
The sign is present and is considered a moderate alteration
The sign is present and is considered a severe alteration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Vaginal Mucosa With Flattening of Folds or Thinning</measure>
    <time_frame>week 3 and week 12 vs baseline</time_frame>
    <description>It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:
0 Absence. The sign is not present.
The sign is present and is considered a mild alteration
The sign is present and is considered a moderate alteration
The sign is present and is considered a severe alteration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Total Score of Signs of Vaginal Atrophy Between Week 3 and Week 12 to Baseline</measure>
    <time_frame>week 3 and week 12 vs baseline</time_frame>
    <description>The signs evaluated Will be the following: vaginal mucosa with flattening of folds or thinning, dryness of the mucosa and Fragility of the mucosa.
It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:
0 Absence. The sign is not present.
The sign is present and is considered a mild alteration
The sign is present and is considered a moderate alteration
The sign is present and is considered a severe alteration A Total Signs Score will be calculated by summing the intensities of all the three signs of vaginal atrophy in a certain time point, thus ranging between 0 and 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Vaginal Maturation Value</measure>
    <time_frame>week 3 and week 12 vs baseline</time_frame>
    <description>Vaginal cytology sample to evaluate the vaginal Maturation Value. For the cytologic evaluation, the number of parabasal, intermediate and superficial cells will be calculated in duplicate on 100 consecutive cells of vaginal cytology. The average of the two percentages obtained for each cell type will be calculated, which will serve to determine the maturation value (MV) based on the following formula:
0.2 x (% parabasal) + 0.6 x (% intermediate) + 1.0 x (% superficial).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Vaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>0.005% estriol vaginal gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo vaginal gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estriol</intervention_name>
    <description>0.005% estriol vaginal gel</description>
    <arm_group_label>0.005% estriol vaginal gel</arm_group_label>
    <other_name>Blissel (estriol)</other_name>
    <other_name>Gelistrol (estriol)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo vaginal gel</description>
    <arm_group_label>placebo vaginal gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent prior to beginning specific protocol procedures.

          2. Patients must have histological confirmation of breast adenocarcinoma with stage
             I-IIIA, documented at a local pathology department.

          3. The breast tumors must be estrogen-receptor positive and/or progesterone receptor
             positive (≥1% of stained tumor cells by Immunohistochemistry (IHC) as determined by
             the local laboratory) with any Human Epidermal Growth Factor Receptor 2(HER2) status.

          4. Postmenopausal status defined as: 12 months of spontaneous amenorrhea or 6 months of
             spontaneous amenorrhea with serum FSH levels &gt; 40 Milli-international units per
             milliliter (mIU/ml) or 6 weeks postsurgical bilateral oophorectomy with or without
             hysterectomy.

          5. Patient must be receiving the non-steroidal aromatase inhibitors anastrozole or
             letrozole as breast cancer treatment in the adjuvant setting for a minimum of 6
             months.

          6. Women suffering from moderate to severe vaginal dryness according to the FDA
             guidelines for drug development in postmenopausal women (Center for Drug Evaluation
             and Research, (CDER) Jan 2003). A moderate symptom will be considered if the symptom
             is present, bothersome and annoying, and a severe symptom will be considered if the
             symptom is present, bothersome and annoying, and interferes with the normal patient
             activity.

          7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.

          8. Adequate bone marrow as defined by the following laboratory values:

               1. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L.

               2. Platelets (plt) ≥ 100 x 109/L.

               3. Hemoglobin (Hgb) ≥ 10 g/dl.

          9. Patient has adequate organ function as defined by the following laboratory values:

               1. Serum creatinine ≤ 1.5 x Upper Limit of Normal (ULN).

               2. Bilirubin ≤ 1.5 × ULN.

               3. Alkaline phosphatase ≤ 2 × ULN.

               4. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2 × ULN.

         10. Willingness and ability to comply with scheduled visits, treatment plan, laboratory
             tests and other study procedures.

        Exclusion Criteria:

          1. Stage IIIB-IV breast cancer or bilateral breast cancer.

          2. Treatment with any other current anti-tumoral therapy (chemotherapy, anti-Her2…etc)
             besides the NSAI. Pamidronate or Alendronate are permitted.

          3. Prior history of other malignancy within 5 years of study entry, aside from
             non-melanoma skin cancer or carcinoma-in-situ of the uterine cervix adequately
             treated.

          4. Postmenopausal uterine bleeding. Vaginal bleeding of unknown etiology.

          5. Patients with endometrial thickness equal to or greater than 4 mm measured by
             transvaginal ultrasound.

          6. Patients who have received any type of vulvovaginal treatment in the 15 days prior to
             the start of the study.

          7. Use of any hormone, natural (phytoestrogens) or herbal products for the treatment of
             menopausal symptoms within the last 3 months.

          8. Current or previous history of thromboembolic disease or coagulopathies.

          9. Severe cardiovascular or respiratory diseases in the previous 6 months.

         10. Renal Impairment.

         11. Hepatitis B and/or hepatitis C carriers (unless with normal hepatic function).

         12. Known human immunodeficiency virus infection.

         13. Known hypersensitivity to NSAI.

         14. Other severe acute or chronic medical or psychiatric condition, or laboratory
             abnormality that would impart, in the judgment of the investigator, excess risk
             associated with study participation or study drug administration, or which, in the
             judgment of the investigator, would make the patient inappropriate for entry into this
             study.

         15. Previous investigational treatment for any condition or participation in any clinical
             trial within 4 weeks of inclusion date.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U.</name>
      <address>
        <city>L´Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U.</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U.</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U.</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U.</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U.</name>
      <address>
        <city>Stockholm</city>
        <zip>171 77</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 1, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <results_first_submitted>August 8, 2018</results_first_submitted>
  <results_first_submitted_qc>June 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 5, 2019</results_first_posted>
  <last_update_submitted>June 21, 2019</last_update_submitted>
  <last_update_submitted_qc>June 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaginal atrophy</keyword>
  <keyword>breast cancer</keyword>
  <keyword>vaginal dryness</keyword>
  <keyword>aromatase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 26, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02413008/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02413008/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study had an initial safety phase of the trial started on March 30th, 2015; the treatment phase of the trial started in October 16th, 2015 and the study ended globally on February 10th, 2017</recruitment_details>
      <pre_assignment_details>After Inform Consent signature and prior randomization the following data was collected for subject’s eligibility: Medical and surgical history and demographics; physical examination, ECOG PS, hematology, blood chemistry, urine test, transvaginal ultrasound, Blood (serum) samples for FSH and LH determination and evaluation of vaginal dryness.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0.005% Estriol Vaginal Gel</title>
          <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration</description>
        </group>
        <group group_id="P2">
          <title>Placebo Vaginal Gel</title>
          <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.005% Estriol Vaginal Gel</title>
          <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
estriol</description>
        </group>
        <group group_id="B2">
          <title>Placebo Vaginal Gel</title>
          <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.9" spread="7.6"/>
                    <measurement group_id="B2" value="61.4" spread="4.7"/>
                    <measurement group_id="B3" value="59.3" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Variation in Serum Levels of Follicle Stimulating Hormone (FSH)</title>
        <description>Change from Baseline (mean screening-baseline) to Week 12 in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability (screening-baseline variation)</description>
        <time_frame>from baseline to 12 weeks of treatment</time_frame>
        <population>postmenopausal participants</population>
        <group_list>
          <group group_id="O1">
            <title>0.005% Estriol Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Variation in Serum Levels of Follicle Stimulating Hormone (FSH)</title>
          <description>Change from Baseline (mean screening-baseline) to Week 12 in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability (screening-baseline variation)</description>
          <population>postmenopausal participants</population>
          <units>mIU/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" lower_limit="-13.1" upper_limit="7.4"/>
                    <measurement group_id="O2" value="1.4" lower_limit="-5.4" upper_limit="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The variations of the levels of FSH after treatment was studied in each women at baseline, week 3 and week12 weeks, the variation of levels between two arms were analysed using a non-parametric test Mann-Whitney-Wilcoxon.
The intra individual variation (differences between the pre study determinations screening and baseline) was compared to the variation between baseline and the values obtained at every study visit.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The primary endpoint, the variation of FSH between week 12 and baseline and also comparing by arm will be analyzed using a non-parametric test (Mann-Whitney-Wilcoxon test).</non_inferiority_desc>
            <p_value>0.10</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The variations in the intensities for each one of the symptoms and signs of the vaginal atrophy, after 3 and 12 weeks, in each treatment arm, will be compared using the non-parametric test Mann-Whitney-Wilcoxon.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The primary endpoint, the variation of FSH between week 12 and baseline and also comparing by arm will be analyzed using a non-parametric test (Mann-Whitney-Wilcoxon test).</non_inferiority_desc>
            <p_value>0.413</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variation in Serum Levels of FSH at Week 1, Week 3 and Week 8</title>
        <description>Change from Baseline (mean screening-baseline) to Week 1, Week 3 and Week 8 in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability ( screening-baseline variation)</description>
        <time_frame>Change from baseline to week 1, week 3 and week 8</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>0.005% Estriol Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
estriol: 0.005% estriol vaginal gel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo: placebo vaginal gel</description>
          </group>
        </group_list>
        <measure>
          <title>Variation in Serum Levels of FSH at Week 1, Week 3 and Week 8</title>
          <description>Change from Baseline (mean screening-baseline) to Week 1, Week 3 and Week 8 in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability ( screening-baseline variation)</description>
          <population>postmenopausal women</population>
          <units>mIU/ml</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change from baseline to week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" lower_limit="-11.6" upper_limit="2.6"/>
                    <measurement group_id="O2" value="4.2" lower_limit="-7.8" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" lower_limit="-12.0" upper_limit="3.5"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-4.0" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" lower_limit="-10.1" upper_limit="7.9"/>
                    <measurement group_id="O2" value="5.2" lower_limit="-11.8" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Variation in serum levels of FSH at week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Dunn Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Variation in serum levels of FSH at week 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Dunn Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Variation in serum levels of FSH at week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Dunn Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variation in Serum Levels of Luteinizing Hormone (LH)</title>
        <description>Change from (mean screening-baseline) in plasma levels of LH to Week 1, Week 3, Week 8 and Week 12 in Serum Levels of LH compare to natural physiological variability ( screening-baseline variation)</description>
        <time_frame>Change from baseline to week 1, week 3, week 8 and week 12</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>0.005% Estriol Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
estriol</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Variation in Serum Levels of Luteinizing Hormone (LH)</title>
          <description>Change from (mean screening-baseline) in plasma levels of LH to Week 1, Week 3, Week 8 and Week 12 in Serum Levels of LH compare to natural physiological variability ( screening-baseline variation)</description>
          <population>postmenopausal women</population>
          <units>mIU/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change from LH baseline to week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-3.7" upper_limit="2.8"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-1.8" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from LH baseline to week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-4.1" upper_limit="3.5"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-1.8" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from LH baseline to week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-4.9" upper_limit="3.1"/>
                    <measurement group_id="O2" value="-1.3" lower_limit="-2.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from LH baseline to week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" lower_limit="-5.3" upper_limit="2.9"/>
                    <measurement group_id="O2" value="1.3" lower_limit="-1.6" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in serum levels of Luteinizing hormone (LH) from baseline to week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Dunn Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in serum levels of Luteinizing hormone (LH) from baseline to week 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Dunn Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in serum levels of Luteinizing hormone (LH) from baseline to week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Dunn Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in serum levels of Luteinizing hormone (LH) from baseline to week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.135</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variation in Plasma Levels of Estriol</title>
        <description>Change in plasma levels of estriol at weeks 1, 3, 8 and 12 compared to baseline</description>
        <time_frame>Change from baseline to week 1, week 3, week 8 and week 12</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>0.005% Estriol Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Variation in Plasma Levels of Estriol</title>
          <description>Change in plasma levels of estriol at weeks 1, 3, 8 and 12 compared to baseline</description>
          <population>postmenopausal women</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change between baseline and week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" lower_limit="-10.7" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change between baseline and week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-3.4" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change between baseline and week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-5.0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change between baseline and week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.8" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to week 1 in plasma levels of estriol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to week 3 in plasma levels of estriol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.649</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to week 8 in plasma levels of estriol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.588</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to week 12 in plasma levels of estriol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variation in Plasma Levels of Estradiol</title>
        <description>Change in plasma levels of estradiol at weeks 1, 3, 8 and 12 compared to baseline.</description>
        <time_frame>Change from baseline to week 1, week 3, week 8 and week 12</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>0.005% Estriol Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
estriol</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Variation in Plasma Levels of Estradiol</title>
          <description>Change in plasma levels of estradiol at weeks 1, 3, 8 and 12 compared to baseline.</description>
          <population>postmenopausal women</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change between baseline and week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change between baseline and week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change between baseline and week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change between baseline and week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to week 1 in plasma levels of estradiol.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.342</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to week 3 in plasma levels of estradiol.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.523</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in plasma levels of estradiol from baseline to week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.523</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in plasma levels of estradiol from baseline to week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.163</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variation in Plasma Levels of Estrona</title>
        <description>Change in plasma levels of estrona at weeks 1, 3, 8 and 12 compared to baseline.</description>
        <time_frame>Change from baseline to week 1, week 3, week 8 and week 12</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>0.005% Estriol Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Variation in Plasma Levels of Estrona</title>
          <description>Change in plasma levels of estrona at weeks 1, 3, 8 and 12 compared to baseline.</description>
          <population>postmenopausal women</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change between baseline and week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in plasma levels of estrona from baseline to week 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.418</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in plasma levels of estrona from baseline to week 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.642</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in plasma levels of estrona from baseline to week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.175</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in plasma levels of estrona from baseline to week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.084</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Vaginal pH Between Baseline and Week 3 and Week 12</title>
        <description>Measurement of vaginal pH on the vaginal secretion using a reactive strip and compare pH value between baseline and the diferent timepoints</description>
        <time_frame>week 3 and week 12 vs baseline</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>0.005% Estriol Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
estriol</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Vaginal pH Between Baseline and Week 3 and Week 12</title>
          <description>Measurement of vaginal pH on the vaginal secretion using a reactive strip and compare pH value between baseline and the diferent timepoints</description>
          <population>postmenopausal women</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.5" upper_limit="2.5"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-0.5" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.5" upper_limit="2.5"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in pH between baseline and week 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in pH between baseline and week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Dyspareunia</title>
        <description>Changes in dyspareunia from baseline to week 3 and week 12 Each symptom will be scored in a numeric scale from 0 to 3, as shown 0 Absence. The symptom is not present
The symptom is of mild intensity, without interfering in the patient's activity
The symptom is of moderate intensity, causing obvious discomfort to the patient
The symptom is stated as very irritating and severe in intensity</description>
        <time_frame>week 3 and week 12 vs baseline</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>0.005% Estriol Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Dyspareunia</title>
          <description>Changes in dyspareunia from baseline to week 3 and week 12 Each symptom will be scored in a numeric scale from 0 to 3, as shown 0 Absence. The symptom is not present
The symptom is of mild intensity, without interfering in the patient's activity
The symptom is of moderate intensity, causing obvious discomfort to the patient
The symptom is stated as very irritating and severe in intensity</description>
          <population>postmenopausal women</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change between baseline and week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change between baseline and week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="2.5"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Changes in dyspareunia from baseline to week 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Changes in dyspareunia from baseline to week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pruritus or Itching From Baseline to Week 3 and Week 12</title>
        <description>Change in pruritus or itching from baseline to week 3 and week 12
Each symptom will be scored in a numeric scale from 0 to 3, as shown below:
0 Absence. The symptom is not present
The symptom is of mild intensity, without interfering in the patient's activity
The symptom is of moderate intensity, causing obvious discomfort to the patient
The symptom is stated as very irritating and severe in intensity</description>
        <time_frame>Change from baseline to week 3 and week 12</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>0.005% Estriol Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pruritus or Itching From Baseline to Week 3 and Week 12</title>
          <description>Change in pruritus or itching from baseline to week 3 and week 12
Each symptom will be scored in a numeric scale from 0 to 3, as shown below:
0 Absence. The symptom is not present
The symptom is of mild intensity, without interfering in the patient's activity
The symptom is of moderate intensity, causing obvious discomfort to the patient
The symptom is stated as very irritating and severe in intensity</description>
          <population>postmenopausal women</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Changes between baseline and week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes between baseline and week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to week 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Vaginal Dryness</title>
        <description>Change in vaginal dryness puntuation score from baseline to w3 and w12
Each symptom will be scored in a numeric scale from 0 to 3, as shown below:
0 Absence. The symptom is not present
The symptom is of mild intensity, without interfering in the patient's activity
The symptom is of moderate intensity, causing obvious discomfort to the patient
The symptom is stated as very irritating and severe in intensity</description>
        <time_frame>week 3 and week 12 vs baseline</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>0.005% Estriol Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
estriol</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Vaginal Dryness</title>
          <description>Change in vaginal dryness puntuation score from baseline to w3 and w12
Each symptom will be scored in a numeric scale from 0 to 3, as shown below:
0 Absence. The symptom is not present
The symptom is of mild intensity, without interfering in the patient's activity
The symptom is of moderate intensity, causing obvious discomfort to the patient
The symptom is stated as very irritating and severe in intensity</description>
          <population>postmenopausal women</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change between baseline and week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change between baseline and week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Changes in vaginal dryness from baseline to week 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Changes in vaginal dryness from baseline to week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Total Score of Symptoms of Vaginal Atrophy</title>
        <description>Changes in Symptoms of vaginal atrophy (vaginal dryness, dyspareunia and pruritus) at week 3 and week 12 vs baseline.
Each symptom will be scored in a numeric scale from 0 to 3, as shown below:
0 Absence. The symptom is not present
The symptom is of mild intensity, without interfering in the patient's activity
The symptom is of moderate intensity, causing obvious discomfort to the patient
The symptom is stated as very irritating and severe in intensity A Global Symptoms Score will be calculated by summing the intensities of all the three symptoms of vaginal atrophy in a certain time point, thus ranging between 0 and 9.</description>
        <time_frame>week 3 and week 12 vs baseline</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>0.005% Estriol Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Total Score of Symptoms of Vaginal Atrophy</title>
          <description>Changes in Symptoms of vaginal atrophy (vaginal dryness, dyspareunia and pruritus) at week 3 and week 12 vs baseline.
Each symptom will be scored in a numeric scale from 0 to 3, as shown below:
0 Absence. The symptom is not present
The symptom is of mild intensity, without interfering in the patient's activity
The symptom is of moderate intensity, causing obvious discomfort to the patient
The symptom is stated as very irritating and severe in intensity A Global Symptoms Score will be calculated by summing the intensities of all the three symptoms of vaginal atrophy in a certain time point, thus ranging between 0 and 9.</description>
          <population>postmenopausal women</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change between baseline and week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.0" upper_limit="4.5"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.5" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change between baseline and week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="3.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.5" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Changes in total score of symptoms of vaginal atrophy from baseline to week 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Changes in total score of symptoms of vaginal atrophy from baseline to week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Dryness of the Mucosa</title>
        <description>It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:
0 Absence. The sign is not present.
The sign is present and is considered a mild alteration
The sign is present and is considered a moderate alteration
The sign is present and is considered a severe alteration</description>
        <time_frame>week 3 and week 12 vs baseline</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>0.005% Estriol Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Dryness of the Mucosa</title>
          <description>It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:
0 Absence. The sign is not present.
The sign is present and is considered a mild alteration
The sign is present and is considered a moderate alteration
The sign is present and is considered a severe alteration</description>
          <population>postmenopausal women</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Changes between baseline and week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes between baseline and week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Changes in dryness of the mucosa between baseline and week 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Changes in dryness of the mucosa betweeen baseline and week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Fragility of the Mucosa [Time Frame: Week 3 and Week 12 vs Baseline]</title>
        <description>It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:
0 Absence. The sign is not present.
The sign is present and is considered a mild alteration
The sign is present and is considered a moderate alteration
The sign is present and is considered a severe alteration</description>
        <time_frame>from baseline to week 3 and 12</time_frame>
        <population>Postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>0.005% Estriol Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Fragility of the Mucosa [Time Frame: Week 3 and Week 12 vs Baseline]</title>
          <description>It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:
0 Absence. The sign is not present.
The sign is present and is considered a mild alteration
The sign is present and is considered a moderate alteration
The sign is present and is considered a severe alteration</description>
          <population>Postmenopausal women</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Changes from baseline to week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from baseline to week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Changes in dryness of the mucosa between baseline and week 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Changes in dryness of the mucosa between baseline and week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Vaginal Mucosa With Flattening of Folds or Thinning</title>
        <description>It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:
0 Absence. The sign is not present.
The sign is present and is considered a mild alteration
The sign is present and is considered a moderate alteration
The sign is present and is considered a severe alteration</description>
        <time_frame>week 3 and week 12 vs baseline</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>0.005% Estriol Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Vaginal Mucosa With Flattening of Folds or Thinning</title>
          <description>It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:
0 Absence. The sign is not present.
The sign is present and is considered a mild alteration
The sign is present and is considered a moderate alteration
The sign is present and is considered a severe alteration</description>
          <population>postmenopausal women</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change between baseline and week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change between baseline and week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to week 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Total Score of Signs of Vaginal Atrophy Between Week 3 and Week 12 to Baseline</title>
        <description>The signs evaluated Will be the following: vaginal mucosa with flattening of folds or thinning, dryness of the mucosa and Fragility of the mucosa.
It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:
0 Absence. The sign is not present.
The sign is present and is considered a mild alteration
The sign is present and is considered a moderate alteration
The sign is present and is considered a severe alteration A Total Signs Score will be calculated by summing the intensities of all the three signs of vaginal atrophy in a certain time point, thus ranging between 0 and 9.</description>
        <time_frame>week 3 and week 12 vs baseline</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>0.005% Estriol Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Total Score of Signs of Vaginal Atrophy Between Week 3 and Week 12 to Baseline</title>
          <description>The signs evaluated Will be the following: vaginal mucosa with flattening of folds or thinning, dryness of the mucosa and Fragility of the mucosa.
It will be scored by the investigator on a numerical scale in accordance with their presence and degree of severity as follows:
0 Absence. The sign is not present.
The sign is present and is considered a mild alteration
The sign is present and is considered a moderate alteration
The sign is present and is considered a severe alteration A Total Signs Score will be calculated by summing the intensities of all the three signs of vaginal atrophy in a certain time point, thus ranging between 0 and 9.</description>
          <population>postmenopausal women</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change between baseline and week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change between baseline and week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="4.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in total score of signs between week 3 and baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in total score of signs between week 12 and baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Vaginal Maturation Value</title>
        <description>Vaginal cytology sample to evaluate the vaginal Maturation Value. For the cytologic evaluation, the number of parabasal, intermediate and superficial cells will be calculated in duplicate on 100 consecutive cells of vaginal cytology. The average of the two percentages obtained for each cell type will be calculated, which will serve to determine the maturation value (MV) based on the following formula:
0.2 x (% parabasal) + 0.6 x (% intermediate) + 1.0 x (% superficial).</description>
        <time_frame>week 3 and week 12 vs baseline</time_frame>
        <population>postmenopausal women</population>
        <group_list>
          <group group_id="O1">
            <title>0.005% Estriol Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration</description>
          </group>
          <group group_id="O2">
            <title>Placebo Vaginal Gel</title>
            <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Vaginal Maturation Value</title>
          <description>Vaginal cytology sample to evaluate the vaginal Maturation Value. For the cytologic evaluation, the number of parabasal, intermediate and superficial cells will be calculated in duplicate on 100 consecutive cells of vaginal cytology. The average of the two percentages obtained for each cell type will be calculated, which will serve to determine the maturation value (MV) based on the following formula:
0.2 x (% parabasal) + 0.6 x (% intermediate) + 1.0 x (% superficial).</description>
          <population>postmenopausal women</population>
          <units>% of cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change between baseline and week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-62.0" lower_limit="-70.04" upper_limit="-37.8"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-11.6" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change between baseline and week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.2" lower_limit="-55.0" upper_limit="-5.4"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-36.4" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in maturation value from baseline to week 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in maturation value from baseline to week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to last visit (up to 16 weeks)</time_frame>
      <desc>AE: Any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>0.005% Estriol Vaginal Gel</title>
          <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration</description>
        </group>
        <group group_id="E2">
          <title>Placebo Vaginal Gel</title>
          <description>Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lymphoma</sub_title>
                <description>An unrelated Serious adverse event (lymphoma) was reported but before study treatment administration</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Concepción Nieto Magro</name_or_title>
      <organization>ITF Research Pharma SLU</organization>
      <phone>0034916572323</phone>
      <email>concepcion@itfsp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

